How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pramlintide-acetate-symlin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

pramlintide acetate (Symlin) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

pramlintide acetate (Symlin) (pramlintide acetate (Symlin)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Amylin receptor agonist. Area: Diabetes.

marketed Amylin receptor agonist Amylin receptor (calcitonin receptor-like receptor with receptor activity-modifying protein 3) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

pramlintide acetate (Symlin) (pramlintide acetate (Symlin)) — AstraZeneca. Pramlintide is a synthetic analog of amylin that slows gastric emptying, suppresses glucagon secretion, and promotes satiety to reduce postprandial glucose excursions in diabetes.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
pramlintide acetate (Symlin) TARGET	pramlintide acetate (Symlin)	AstraZeneca	marketed	Amylin receptor agonist	Amylin receptor (calcitonin receptor-like receptor with receptor activity-modifying protein 3)
Placebo cagrilintide	Placebo cagrilintide	Novo Nordisk A/S	phase 3	Amylin receptor agonist	Amylin receptor (calcitonin receptor-like receptor with receptor activity-modifying protein 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Amylin receptor agonist class)

AstraZeneca · 1 drug in this class
Novo Nordisk A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). pramlintide acetate (Symlin) — Competitive Intelligence Brief. https://druglandscape.com/ci/pramlintide-acetate-symlin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing